JAK2 and essential thrombocythemia: The aforementioned findings corroborate another study in which a gradual increase in the JAK2 V617F allele burden was the most powerful predictor of PV/ET progression to secondary MF during cytoreductive therapy (hazard ratio 10.8) [71].